Bicara Therapeutics grants options to director

Bicara Therapeutics director Jeremy Bender reported an equity compensation award in the form of a Stock Option (Right to Buy) covering 38,950 shares of common stock.

Rhea-AI Filing Summary

Bicara Therapeutics director Jeremy Bender reported an equity compensation award in the form of a Stock Option (Right to Buy) covering 38,950 shares of common stock. The option has an exercise price of $26.88 per share and expires on July 28, 2036. One-third of the shares underlying the option vest and become exercisable on July 28, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to his continued service on each vesting date.

Insider Trade Summary

Grant/Award: 38,950 shares

Grant/Award 1 txn

Insider Bender Jeremy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	38,950	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 38,950 contracts (Direct)

Footnotes (1)

1. F1. One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Stock options granted: 38,950 shares Exercise price: $26.88 per share Option expiration date: 2036-07-28 +1 more

4 metrics

Stock options granted 38,950 shares Grant of Stock Option (Right to Buy) on 2026-07-28 to a director

Exercise price $26.88 per share Conversion or exercise price of the stock option

Option expiration date 2036-07-28 Expiration date of the Stock Option (Right to Buy)

Initial vesting date July 28, 2027 One-third of the shares underlying this option vest and become exercisable on this date

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest and become exercisable

4 terms

Stock Option (Right to Buy) financial

"Security title reported as Stock Option (Right to Buy) for the award"

exercise price financial

"Conversion or exercise price of $26.8800 per share for the option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The option carries an expiration date of 2036-07-28"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become exercisable financial

"One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Jeremy Bender report for BCAX?

Jeremy Bender reported a grant of stock options for 38,950 shares of Bicara Therapeutics common stock. These options carry a $26.88 exercise price, vest over time starting in 2027, and represent equity-based compensation for his role as a director.

How many stock options were granted to Jeremy Bender in this BCAX filing?

The filing reports a grant of 38,950 stock options to director Jeremy Bender. Each option relates to one share of Bicara Therapeutics common stock, providing potential future ownership if exercised once the options have vested and are in-the-money.

What is the exercise price and expiration date of Bender's BCAX options?

The options have an exercise price of $26.88 per share and an expiration date of July 28, 2036. This means Bender may purchase shares at $26.88, once vested, any time before the option term ends in 2036.

How do the stock options for BCAX vest for Jeremy Bender?

The options vest in stages: one-third of the underlying shares vest and become exercisable on July 28, 2027. The remaining shares vest in 24 equal monthly installments after that date, conditioned on Bender’s continued service on each vesting date.

Was the BCAX insider transaction reported under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not selected, so this grant is not reported as made under a pre-arranged Rule 10b5-1 trading plan. It is presented simply as an equity award to a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 04:19 PM Accepted by SEC EDGAR 07/29/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bender Jeremy

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$26.88	07/28/2026		A		38,950		(1)	07/28/2036	Common Stock	38,950	$0	38,950	D

Explanation of Responses:

1. One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Ryan Cohlhepp, Attorney-in-Fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)